Ryan Fukushima Sells 14,286 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Ryan Fukushima sold 14,286 shares of Tempus AI stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $70.00, for a total transaction of $1,000,020.00. Following the completion of the transaction, the chief executive officer directly owned 47,420 shares in the company, valued at approximately $3,319,400. The trade was a 23.15% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Fukushima also recently made the following trade(s):

• On Tuesday, August 18th, Ryan Fukushima sold 41,095 shares of Tempus AI stock. The stock was sold at an average price of $49.61, for a total transaction of $2,038,722.95.
• On Friday, August 7th, Ryan Fukushima sold 20,000 shares of Tempus AI stock. The stock was sold at an average price of $50.04, for a total transaction of $1,000,800.00.
• On Monday, August 3rd, Ryan Fukushima sold 23,818 shares of Tempus AI stock. The stock was sold at an average price of $46.19, for a total value of $1,100,153.42.
• On Wednesday, July 8th, Ryan Fukushima sold 33,284 shares of Tempus AI stock. The stock was sold at an average price of $57.39, for a total value of $1,910,168.76.
• On Monday, July 6th, Ryan Fukushima sold 10,000 shares of Tempus AI stock. The stock was sold at an average price of $60.00, for a total transaction of $600,000.00.

Tempus AI Stock Down 0.4%

Shares of TEM stock opened at $68.48 on Thursday. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06. The firm’s fifty day moving average price is $53.97 and its two-hundred day moving average price is $51.60. The firm has a market capitalization of $12.36 billion, a P/E ratio of -47.56 and a beta of 3.58. Tempus AI, Inc. has a 1 year low of $40.77 and a 1 year high of $104.32.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The firm had revenue of $382.49 million during the quarter, compared to the consensus estimate of $379.69 million. During the same period last year, the company earned ($0.22) earnings per share. The business’s revenue was up 21.6% compared to the same quarter last year. On average, equities analysts predict that Tempus AI, Inc. will post -1.38 EPS for the current fiscal year.

Institutional Investors Weigh In On Tempus AI

Hedge funds have recently modified their holdings of the company. JPL Wealth Management LLC acquired a new position in shares of Tempus AI in the third quarter valued at approximately $26,000. Los Angeles Capital Management LLC acquired a new position in Tempus AI in the 4th quarter valued at approximately $27,000. EMC Capital Management bought a new position in shares of Tempus AI during the second quarter valued at $29,000. Harvest Fund Management Co. Ltd acquired a new position in shares of Tempus AI during the third quarter worth $38,000. Finally, Whittier Trust Co. grew its stake in shares of Tempus AI by 190.0% in the first quarter. Whittier Trust Co. now owns 870 shares of the company’s stock worth $41,000 after purchasing an additional 570 shares during the last quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on TEM. Weiss Ratings raised shares of Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 12th. Lake Street Capital lowered Tempus AI to a “hold” rating in a research note on Monday, July 20th. Needham & Company LLC reissued a “buy” rating and set a $75.00 price target on shares of Tempus AI in a report on Friday, July 31st. TD Cowen restated a “buy” rating on shares of Tempus AI in a research note on Wednesday, July 15th. Finally, Guggenheim upped their price objective on Tempus AI from $60.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Nine investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $65.69.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.